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INTRODUCTION
Resin-containing materials are used routinely in dental practice as directfilling materials, fissure sealing agents, bonding resins, and resin
cements. Among the components of most bonding and restorative resins are:
(1) a primary resin, usually bisphenol-A-glycidyldimethacrylate (BisGMA);
and (2) triethyleneglycoldimethacrylate (TEGDMA), which is included to
compensate for the high viscosity of the primary resin. Resin composites
contain BisGMA in amounts varying from 5-9 wt% (Munksgaard et al.,
2000), while fissure sealants contain BisGMA in the range 10-50%
(Komurcuoglu et al., 2005).
Direct evidence of BisGMA release from composite resins and fissure
sealants into the biophase was provided previously (Tanaka et al., 1991;
Spahl et al., 1998; Nalcaci et al., 2006). Released dental material
components can be expected to enter the body by 2 different routes after
resin placement, via the saliva and gastrointestinal tract, plus (if the material
is placed on dentin) via the dentin and pulp (Hume and Gerzina, 1996).
To test the hypothesis that BisGMA reaches cytotoxic levels in body
tissues, and to develop an understanding of the whole-body kinetics of
BisGMA, we measured the uptake, distribution, and clearance of
[14C]BisGMA administered by gastric tube and by intravenous injection in
guinea pigs.
MATERIALS & METHODS
[14C]BisGMA was purchased from Perkin Elmer (Boston, MA, USA), dissolved
in dichloromethane, and stored at -20°C. Unlabeled BisGMA was obtained from
Degussa (Frankfurt, Germany).
In situ Experiments
Guinea pigs were randomized and allotted to 3 groups of 4 animals each. The
animals were anesthetized with urethane (1 mg/kg, 4 mL/kg; dissolved in 0.9%
NaCl solution). The ductus cysticus was ligated, and a cannula was placed in the
bile duct, as described in previous experiments (Reichl et al., 2001). A 1 mL/kg
quantity of BisGMA, dissolved in DMSO (final DMSO concentration, 1%), was
injected via the jugular vein [0.02 mol/kg body weight (bw), labeled with a
tracer dose of [14C]BisGMA, 0.3 kBq/g bw] (group 1). Control animals (groups 2
and 3) received either 0.9% NaCl solution or DMSO (final DMSO concentration,
1% in 0.9% NaCl solution), each without BisGMA. Blood was withdrawn from
the carotid artery. Samples of the bile (0.4 mL) and blood (0.2 mL) were taken
every 10 min. The experimental period was 60 min. The organs and their contents
were immediately removed and their [14C]-radioactivity measured.
In vivo Experiments
Adult male guinea pigs (Dunkin-Hartley Pirbright white strain, 400 g), were fed
a standard diet and water ad libitum. Twelve guinea pigs were allotted to 3
groups of 4 animals each. Each animal was put into a separate metabolic cage 3
days before and food was removed 12 hrs before the experiment. Each animal
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received BisGMA (0.02 mol/kg bw, dissolved 1% DMSO
solution, labeled with a tracer dose of [14C]BisGMA, 0.3 kBq/g
bw) via gastric tube (group 4). Control animals (groups 5 and 6)
received either 0.9% NaCl solution or DMSO (final DMSO
concentration, 1%), each without BisGMA. The volume for the
application through the gastric tube was 4 mL/kg. Feces and urine
were collected at 1, 2, 4, 6, 8, 12, and 24 hrs after [14C]BisGMA
administration, and the [14C]-radioactivity was measured as
described below. Twenty-four hrs after the beginning of the
experiment, the animals were killed in ether. The organs and their
contents were immediately removed and their [14C]-radioactivity
measured. Details of organ treatment and the method of
determination of radioactivity are in the APPENDIX. Data are
presented as means ± SEM. Statistical significance of the
differences between the experimental groups was determined by
the Bonferroni-Holm t test (Sheskin, 2007).
A second set of 12 guinea pigs was treated as described
above, with the addition that each animal was kept in a closed
chamber with controlled air flow. The exhaled air was captured
during the 24-hour experimental period by flowing through 7
bottles, 1 behind the other, filled with 250 mL ice-cold 5 N NaOH
(see Fig.). [14C]-carbon dioxide was captured as [14C]-Na
2
CO
3
and
the total [14C] activity determined. Urine and feces were collected
at 24 hrs after the beginning of the experiment, and the animals
were killed and organs taken for analysis as described for the first
in vivo experimental group.
Declaration
These experiments complied with the current laws of Germany.
The animal experiments were approved by the Regierung von
Oberbayern, permission no. 211-2531-66/94.
The accession number for 14C compounds is: 4/4-8816.352-
14783, Bayerisches Landesamt für Umweltschutz, Augsburg,
Germany.
Guinea Pig Organs
Organs taken and tested were: liver, kidney, blood, skin, brain,
heart, spleen, lung, muscle, testes, eyes, bone, nerve tissue, spinal
cord, wall of stomach, content of stomach, wall of ileum +
jejunum, content of ileum + jejunum, wall of colon, content of
colon, wall of caecum, content of caecum, wall of gall bladder, and
fat tissue. Organs were immediately washed with 2 x 10 mL
distilled H
2
O, the wash-water was saved, and then the tissues were
weighed and homogenized.
Determination of Radioactivity, Guinea Pig Experiments
Tissues were dissolved in tetraethylammoniumhydroxide (TEAH)
(20%) in aqueous solution with Omni-Szintisol® (both from
Merck, Darmstadt, Germany). Radioactivity was determined by the
method described by Strugala (1984), with a liquid scintillation
counter (2500 TR, Canberra-Packard, Dreieich, Germany).
RESULTS
[14C] Recovery from Guinea Pigs after 1 Hr
During the first hr after [14C]BisGMA intravenous injection,
about 12% of the [14C] was excreted via the bile, and about
50% remained in the tissues at 1 hr, the time the guinea pigs
were killed (Table 1). [14C] activity was rapidly removed from
the blood (Table 1). Additional data on [14C] distribution in the
bile and blood and [14C] activity in various organs are included
in the APPENDIX.
[14C] Recovery from Guinea Pigs after 24 Hrs
During the first 24 hrs after [14C]BisGMA oral administration,
guinea pigs exhaled 14CO
2
equivalent to about 65% of the
[14C]BisGMA dose administered (Table 2). About 7% of the
[14C] was excreted via urine, and about 6% remained in the
tissues at 24 hrs, the time the guinea pigs were killed (Table 2).
The total [14C] recovery was about 85% of the [14C]BisGMA
dose administered (Table 2). Additional data on fecal and
urinary volumes, [14C] excretion, and [14C] activity in various
organs are included in the APPENDIX.
Figure. Metabolic cage with controlled air flow for capturing [14C]-
carbon dioxide. Exhaled carbon dioxide was captured by pumping the
exhaled air through bottles 1-7, each filled with ice-cold 5 N NaOH.
Table 1. [14C] Recovery in Guinea Pigs in the Bile and Blood, as well as
Summed [14C] Distribution in Organs 1 hr after Intravenous
[14C]BisGMA Injection (n = 4; mean ± SEM)
[14C] Activity
(% of the [14C]BisGMA dose administered)
Intravenous Injection
Mean SEM
Bile 12.0 2.1
Blood 1.1 0.1
Organ wash water 0.8 0.2
 organs 49.6 5.5
Table 2. [14C] Excretion in Guinea Pigs via the Urine, Feces, and
Carbon Dioxide as well as Summed [14C] Distribution in Organs 24 hrs
after [14C]BisGMA Administration with a Gastric Tube (n = 4; mean ±
SEM)
[14C] Activity
(% of the [14C]BisGMA dose administered)
Application with the Gastric Tube
Mean SEM
Urine 7.3 1.1
Feces 5.0 0.8
Exhaled 14CO2 65.3 2.3
Organ wash water 1.2 0.2
 organs 5.8 0.9
Total [14C] recovery 84.6 2.8
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DISCUSSION
The administered dose levels were chosen to exceed
substantially the body-weight-adjusted dose levels relative to
humans for BisGMA released from large composite resin
restorations. For the guinea pig experiments, we used the data
of Munksgaard et al. (2000), who measured extracted
quantities from polymerized composites eluted for 7 days with
water. The values for various composite components eluted in
these chemical experiments ranged from 0.03 to 0.07 wt% in
water. The highest eluted BisGMA level into water shown by
Munksgaard et al. (2000) was from the commercial composite
Z100® (3M ESPE, Seefeld, Germany), which provided about
1.5 mol BisGMA from 16 g composite. Assuming the worst
case, that all restorations in all teeth are replaced by Z100 (32
teeth; about 0.5 grams per tooth/filling = about 16 g Z100), a
dose level equivalent to the total amount released from this
material was used and adjusted by proportion with the body
weight of the average human (1.5 mol BisGMA/70 kg bw =
0.02 mol/kg bw).
Analysis of our data showed that uptake of [14C]BisGMA
from the stomach and intestine of guinea pigs was rapid and
essentially complete, and that distribution of [14C]BisGMA
and/or its metabolites throughout the body with these routes of
administration was broad. More than 65% of the administered
[14C] was excreted via the lungs as 14CO
2
in guinea pigs, while
some 7% of the administered [14C] appeared in the urine. Most
of the [14C] label was cleared from the body one day following
gastric administration.
The cumulative biliary [14C] excretion was about 2 times
higher after 60 min than the cumulative fecal [14C] excretion
after 24 hrs. Therefore, enterohepatic recycling of
[14C]BisGMA and/or [14C]BisGMA metabolite(s) cannot be
excluded. Enterohepatic recycling and similar biological
clearances have also been described for HEMA and TEGDMA
in guinea pigs (Reichl et al., 2001, 2002). Analysis of the
present data indicates the existence of similar mechanisms for
uptake and biliary excretion for HEMA, TEGDMA, and
BisGMA.
We did not determine where, in the organism, BisGMA
was metabolized to carbon dioxide. However, the moderately
elevated levels in the lung relative to other tissues after
intravenous or oral administration suggest metabolic
conversion in that tissue. Furthermore, metabolism of BisGMA
and formation of CO
2
from BisGMA appear to be independent
of these routes of administration, i.e., metabolism of BisGMA
in the stomach and/or in the intestine is very unlikely. Further
discussion about possible metabolic pathways and distribution
and clearance following intravenous and oral administration is
included in the APPENDIX.
Despite the fact that the body-weight-adjusted dose of
BisGMA administered was more than 20 times higher than that
which would be encountered by a human, the highest levels of
BisGMA observed in tissue samples taken from guinea pigs,
1.5 nano M in the lung, 1 hr after intraveneous injection are
approximately 1000-fold less than the known toxic level for
BisGMA (Kostoryz et al., 2003; Schwengberg et al., 2005;
Reichl et al., 2006; Schweikl et al., 2006).
Similarly, with a dose well in excess of the weight-
adjusted, expected equivalent in humans, the highest [14C]
concentration in the spontaneous urine in guinea pigs was
found 4 hrs after the oral [14C] application (1.2% in 1.4 mL).
Peak levels in blood and kidney tissue occurred much earlier
than this, which is consistent with the known time dynamics of
urine production and the variable (but expected) delay before
urine release. Calculated from this [14C] peak concentration in
the urine at the dose administered, a peak BisGMA
concentration in the spontaneous urine can be estimated at
about 0.2 nmol/L. This concentration is at least 1/500,000th of
the level that decreased the cell survival ratio in kidney cells
(Hikage et al., 1999). It is therefore unlikely that BisGMA
released from restorative materials could have any systemic,
toxic effects. However, it is noted that only general cytotoxic
effects were investigated in association with BisGMA, and
there may be many as-yet-uninvestigated toxic effects
generated in various cells by this substance.
The possibility of allergic responses in patients and in
dental workers is discussed in the APPENDIX.
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